USA - NASDAQ:CRMD - US21900C3088 - Common Stock
The current stock price of CRMD is 11.65 USD. In the past month the price increased by 1.84%. In the past year, price decreased by -10.66%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 49.51 | 756.76B | ||
JNJ | JOHNSON & JOHNSON | 18.49 | 462.11B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 18.74 | 258.03B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 14.84 | 254.25B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 14.05 | 243.41B | ||
MRK | MERCK & CO. INC. | 11.38 | 218.86B | ||
PFE | PFIZER INC | 7.33 | 141.29B | ||
SNY | SANOFI-ADR | 11.21 | 121.02B | ||
GSK | GSK PLC-SPON ADR | 9.76 | 88.38B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.62 | 90.66B | ||
ZTS | ZOETIS INC | 23.49 | 64.74B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 48.66 | 44.56B |
CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company is headquartered in Berkeley Heights, New Jersey and currently employs 64 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The firm is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The firm is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
CORMEDIX INC
300 Connell Drive, Suite 4200
Berkeley Heights NEW JERSEY 07922 US
CEO: Khoso Baluch
Employees: 65
Phone: 19085179500
The current stock price of CRMD is 11.65 USD. The price decreased by -4.19% in the last trading session.
The exchange symbol of CORMEDIX INC is CRMD and it is listed on the Nasdaq exchange.
CRMD stock is listed on the Nasdaq exchange.
13 analysts have analysed CRMD and the average price target is 20.91 USD. This implies a price increase of 79.48% is expected in the next year compared to the current price of 11.65. Check the CORMEDIX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CORMEDIX INC (CRMD) has a market capitalization of 869.67M USD. This makes CRMD a Small Cap stock.
CORMEDIX INC (CRMD) currently has 65 employees.
CORMEDIX INC (CRMD) has a support level at 10.17 and a resistance level at 12.16. Check the full technical report for a detailed analysis of CRMD support and resistance levels.
The Revenue of CORMEDIX INC (CRMD) is expected to grow by 525.46% in the next year. Check the estimates tab for more information on the CRMD EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CRMD does not pay a dividend.
CORMEDIX INC (CRMD) will report earnings on 2025-11-06, before the market open.
The PE ratio for CORMEDIX INC (CRMD) is 15.53. This is based on the reported non-GAAP earnings per share of 0.75 and the current share price of 11.65 USD. Check the full fundamental report for a full analysis of the valuation metrics for CRMD.
The outstanding short interest for CORMEDIX INC (CRMD) is 24.21% of its float. Check the ownership tab for more information on the CRMD short interest.
ChartMill assigns a technical rating of 3 / 10 to CRMD. When comparing the yearly performance of all stocks, CRMD is a bad performer in the overall market: 74.74% of all stocks are doing better.
ChartMill assigns a fundamental rating of 7 / 10 to CRMD. CRMD has an excellent financial health rating, but there are some minor concerns on its profitability.
Over the last trailing twelve months CRMD reported a non-GAAP Earnings per Share(EPS) of 0.75. The EPS increased by 180.65% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 42.11% | ||
ROA | 20.25% | ||
ROE | 23.19% | ||
Debt/Equity | 0 |
13 analysts have analysed CRMD and the average price target is 20.91 USD. This implies a price increase of 79.48% is expected in the next year compared to the current price of 11.65.
For the next year, analysts expect an EPS growth of 590.65% and a revenue growth 525.46% for CRMD